Literature DB >> 27498003

MiR-509-3-5p causes aberrant mitosis and anti-proliferative effect by suppression of PLK1 in human lung cancer A549 cells.

Xian-Hui Wang1, Yao Lu1, Jing-Jing Liang1, Ji-Xiang Cao1, Ya-Qiong Jin2, Guo-Shun An1, Ju-Hua Ni1, Hong-Ti Jia1, Shu-Yan Li3.   

Abstract

MicroRNAs (miRNAs) are potent post-transcriptional regulators of gene expression and play roles in DNA damage response (DDR). PLK1 is identified as a modulator of DNA damage checkpoint. Although down-regulation of PLK1 by certain microRNAs has been reported, little is known about the interplay between PLK1 and miR-509-3-5p in DDR. Here we have demonstrated that miR-509-3-5p repressed PLK1 expression by targeting PLK1 3'-UTR, thereby causing mitotic aberration and growth arrest of human lung cancer A549 cells. Repression of PLK1 by miR-509-3-5p was further evidenced by over-expression of miR-509-3-5p in A549, HepG2 and HCT116p53(-/-) cancer cells, in which PLK1 protein was suppressed. Consistently, miR-509-3-5p was stimulated, while PLK1 protein was down-regulated in A549 cells exposed to CIS and ADR, suggesting that suppression of PLK1 by miR-509-3-5p is a component of CIS/ADR-induced DDR pathway. Flow cytometry and immunofluorescence labeling showed that over-expression of miR-509-3-5p in A549 induced G2/M arrest and aberrant mitosis characterized by abnormal bipolar mitotic spindles, condensed chromosomes, lagging DNA and chromosome bridges. In addition, over-expression of miR-509-3-5p markedly blocked A549 cell proliferation and sensitized the cells to CIS and ADR treatment. Taken together, miR-509-3-5p is a feasible suppressor for cancer by targeting PLK1. Our data may provide aid in potential design of combined chemotherapy and in our better understanding of the roles of microRNAs in response to DNA damage.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aberrant mitosis; Adriamycin; Cisplatin; DNA damage response; PLK1; miR-509-3-5p

Mesh:

Substances:

Year:  2016        PMID: 27498003     DOI: 10.1016/j.bbrc.2016.08.006

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  Plk1 promotes the migration of human lung adenocarcinoma epithelial cells via STAT3 signaling.

Authors:  Weijuan Yan; Huijie Yu; Wei Li; Fengsheng Li; Sinian Wang; Nan Yu; Qisheng Jiang
Journal:  Oncol Lett       Date:  2018-09-14       Impact factor: 2.967

Review 2.  miRNA dysregulation is an emerging modulator of genomic instability.

Authors:  Ana P Ferragut Cardoso; Mayukh Banerjee; Alexandra N Nail; Angeliki Lykoudi; J Christopher States
Journal:  Semin Cancer Biol       Date:  2021-05-09       Impact factor: 15.707

Review 3.  Interactions between anticancer active platinum complexes and non-coding RNAs/microRNAs.

Authors:  Bernhard Biersack
Journal:  Noncoding RNA Res       Date:  2016-10-13

4.  A six-microRNA signature to predict outcomes of patients with gastric cancer.

Authors:  Jian Chen; Bing Hu; Wei Wang; Xiao-Jun Qian; Ben-Jie Shan; Yi-Fu He
Journal:  FEBS Open Bio       Date:  2019-01-31       Impact factor: 2.693

5.  Integrative Analysis of miRNA and mRNA Expression Profiles Associated With Human Atrial Aging.

Authors:  Yan Yao; Chenxi Jiang; Fan Wang; Han Yan; Deyong Long; Jinghua Zhao; Jiangang Wang; Chunxiao Zhang; Yang Li; Xiaoli Tian; Qing K Wang; Gang Wu; Zhihui Zhang
Journal:  Front Physiol       Date:  2019-09-19       Impact factor: 4.566

6.  Somatic Mutations in miRNA Genes in Lung Cancer-Potential Functional Consequences of Non-Coding Sequence Variants.

Authors:  Paulina Galka-Marciniak; Martyna Olga Urbanek-Trzeciak; Paulina Maria Nawrocka; Agata Dutkiewicz; Maciej Giefing; Marzena Anna Lewandowska; Piotr Kozlowski
Journal:  Cancers (Basel)       Date:  2019-06-08       Impact factor: 6.639

Review 7.  MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas.

Authors:  Irina Fadejeva; Horst Olschewski; Andelko Hrzenjak
Journal:  Oncotarget       Date:  2017-12-05

8.  CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway.

Authors:  Dawoon E Jung; Soo Been Park; Kahee Kim; Chanyang Kim; Si Young Song
Journal:  Sci Rep       Date:  2017-09-07       Impact factor: 4.379

9.  miR-509-3-5P inhibits the invasion and lymphatic metastasis by targeting PODXL and serves as a novel prognostic indicator for gastric cancer.

Authors:  Jing Zhang; Zhonglin Zhu; Jinxin Sheng; Zhilong Yu; Bin Yao; Kejian Huang; Lisheng Zhou; Zhengjun Qiu; Chen Huang
Journal:  Oncotarget       Date:  2017-05-23

10.  The novel GINS4 axis promotes gastric cancer growth and progression by activating Rac1 and CDC42.

Authors:  Zhonglin Zhu; Zhilong Yu; Zeyin Rong; Zai Luo; Jing Zhang; Zhengjun Qiu; Chen Huang
Journal:  Theranostics       Date:  2019-10-21       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.